AstraZeneca: No Talks With Trump On Emergency Use Authorization For COVID-19 Vaccine
Politicization Could Undermine Public Faith In Vaccine
Reports come as tensions around the independence of the US FDA mount, and data readouts from the first vaccines could emerge before US election day on 3 November.
You may also be interested in...
AstraZeneca – one of the frontrunners in the race to develop a COVID-19 vaccine – has voluntarily put a hold on the Phase III trial due to an adverse event.
US FDA Commissioner Hahn’s controversial statement about approval before the end of Phase III has at least one taker, which may concern public health observers.
While AstraZeneca’s adenovirus candidate is expected to use Operation Warp Speed’s platform, its start date remains cloaked; the Janssen and Novavax candidates are expected to enter Phase III in September and October, respectively.